411 related articles for article (PubMed ID: 11170948)
1. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
Rubinstein E; Cammarata S; Oliphant T; Wunderink R;
Clin Infect Dis; 2001 Feb; 32(3):402-12. PubMed ID: 11170948
[TBL] [Abstract][Full Text] [Related]
2. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
[TBL] [Abstract][Full Text] [Related]
3. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
[TBL] [Abstract][Full Text] [Related]
4. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
5. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
8. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
9. [Linezolid versus vancomycin in the treatment of pneumonia caused by Gram-positive cocci: meta-analysis of randomised controlled trials].
Lin ZQ; Huang YL; Huang P; Chen Q
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Dec; 33(12):900-6. PubMed ID: 21211409
[TBL] [Abstract][Full Text] [Related]
10. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
[TBL] [Abstract][Full Text] [Related]
11. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
12. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
[TBL] [Abstract][Full Text] [Related]
14. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections.
Sirvent JM; Piñeiro L; de la Torre M; Motjé M; de Batlle J; Bonet A
Rev Esp Quimioter; 2010 Mar; 23(1):27-35. PubMed ID: 20232021
[TBL] [Abstract][Full Text] [Related]
15. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
Shorr AF; Kunkel MJ; Kollef M
J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
17. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
[TBL] [Abstract][Full Text] [Related]
18. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
[TBL] [Abstract][Full Text] [Related]
19. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
20. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Puzniak LA; Morrow LE; Huang DB; Barreto JN
Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
